Filtered By:
Therapy: Immunotherapy

This page shows you your search results in order of date.

Order by Relevance | Date

Total 325 results found since Jan 2013.

Hydrogel Drug Delivery Systems for Minimally Invasive Local Immunotherapy of Cancer
Adv Drug Deliv Rev. 2023 Sep 4:115083. doi: 10.1016/j.addr.2023.115083. Online ahead of print.ABSTRACTAlthough systemic immunotherapy has achieved durable responses and improved survival for certain patients and cancer types, low response rates and immune system-related systemic toxicities limit its overall impact. Intratumoral (intralesional) delivery of immunotherapy is a promising technique to combat mechanisms of tumor immune suppression within the tumor microenvironment and reduce systemic drug exposure and associated side effects. However, intratumoral injections are prone to variable tumor drug distribution and leak...
Source: Advanced Drug Delivery Reviews - September 6, 2023 Category: Drugs & Pharmacology Authors: Andrew S Mikhail Robert Morhard Michal Mauda-Havakuk Michael Kassin Antonio Arrichiello Bradford J Wood Source Type: research

Sonodynamic amplification of cGAS-STING activation by cobalt-based nanoagonist against bone and metastatic tumor
Biomaterials. 2023 Aug 26;302:122295. doi: 10.1016/j.biomaterials.2023.122295. Online ahead of print.ABSTRACTThe therapeutic effect of cancer immunotherapy is restrained by limited patient response rate caused by 'cold' tumors with an intrinsically immunosuppressive tumor microenvironment (TME). Activating stimulator of interferon genes (STING) confers promising antitumor immunity even in 'cold' tumors, but the further promotion of STING agonists is hindered by undesirable toxicity, low specificity and lack of controllability. Herein, an ultrasound-controllable cGAS-STING amplifying nanoagonist was constructed by coordinat...
Source: Biomaterials - September 4, 2023 Category: Materials Science Authors: Jie Lei Weifeng Zhang Liang Ma Yaqi He Huaizhen Liang Xiaoguang Zhang Gaocai Li Xiaobo Feng Lei Tan Cao Yang Source Type: research

CU06-1004 as a promising strategy to improve anti-cancer drug efficacy by preventing vascular leaky syndrome
Conclusion: Our data suggest that CU06-1004 acts as a potential anticancer drug candidate, not only by preventing HDIL-2-induced VLS but also by enhancing the anticancer effects of HDIL-2 immunotherapy.
Source: Frontiers in Pharmacology - August 30, 2023 Category: Drugs & Pharmacology Source Type: research

Cancers, Vol. 15, Pages 3908: A Systematic Review of Short-Term Outcomes of Minimally Invasive Thoracoscopic Surgery for Lung Cancer after Neoadjuvant Systemic Therapy
Conclusions: The current literature supports VATS as safe and feasible for patients with NSCLC after neoadjuvant systemic treatment. Surgeons should remain prepared to convert to open surgeries in those patients with dense adhesions and bleeding risk.
Source: Cancers - August 1, 2023 Category: Cancer & Oncology Authors: Shaina Sedighim Madelyn I. Frank Olivia Heutlinger Carlin Lee Stephanie J. Hachey Hari B. Keshava Tags: Systematic Review Source Type: research

Ad hoc announcement pursuant to Art. 53 LR Roche reports strong growth in both divisions ’ base business; Group sales and profit reflect declining demand for COVID-19 products
Excluding COVID-19 products,Groupsales increase strongly by 8%1at constant exchange rates (CER)In line with the expected declining demand for COVID-19 products,Groupsales decrease 2% (-8% in Swiss francs)Pharmaceuticals Division sales grow strongly by 8% due to continued high demand for newer medicines; new eye medicine Vabysmo is the strongest growth driverDiagnostics Division ’s base businesscontinues its good growth momentum with an increase of 6%, while total divisional sales are 23% lower due to exceptionally high demand for COVID-19 tests in the first half of 2022Core earnings per share decrease 5%, driven by lower...
Source: Roche Investor Update - July 27, 2023 Category: Pharmaceuticals Source Type: news

Fight Aging! Newsletter, May 15th 2023
In this study, we examined the average telomere length and telomerase activity, as well as the formation of telomere associated foci (TAFs) and the mRNA expression levels of the shelterin components in cultured primary cells of Spalax, a long-lived, hypoxia-tolerant, and cancer-resistant blind mole-rat species. We showed that with cell passages, Spalax fibroblasts demonstrated significant shortening in telomere length, similar to rat cells, and in line with the processes observed earlier in tissues. We also demonstrated that the average telomere length in Spalax fibroblasts was significantly higher than the average ...
Source: Fight Aging! - May 14, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Elimination of methicillin-resistant Staphylococcus aureus biofilms on titanium implants via photothermally-triggered nitric oxide and immunotherapy for enhanced osseointegration
ConclusionsThese findings suggest that Ti-PDA@SNP-OGP is a promising multi-functional material for the high-efficient treatment of MRSA infections in implant replacement surgeries.
Source: Military Medical Research - May 4, 2023 Category: International Medicine & Public Health Source Type: research

Ad hoc announcement pursuant to Art. 53 LR Roche reports strong sales growth in base business of both divisions in the first quarter; Group sales decline due to expected drop in demand for COVID-19 tests
As expected, significantly lower demand for COVID-19 tests leads to a decrease inGroup sales (-3%1 at constant exchange rates [CER] and -7% in Swiss francs); excluding this effect, Group sales grow 8%Pharmaceuticals Divisionsales up 9%; strong demand for newer medicines; Vabysmo for severe eye diseases is already the strongest growth driverDiagnostics Division base business grows 4%, whiledivisional salesare 28% lower due to exceptionally high demand for COVID-19 tests in the first quarter of 2022Highlights in the first quarter:US approval of  Polivy (first-line treatment for an aggressive form of blood cancer)EU approva...
Source: Roche Investor Update - April 26, 2023 Category: Pharmaceuticals Source Type: news

Cancers, Vol. 15, Pages 2462: Surgical Resection of Pulmonary Metastases from Melanoma in Oligometastatic Patients: Results from a Multicentric Study in the Era of Immunoncology and Targeted Therapy
esto Rossi Leonardo Petracca-Ciavarella Maria Letizia Vita Marco Chiappetta Alessandra Siciliani Valentina Peritore Mattia Manitto Lucia Morelli Edoardo Zanfrini Diomira Tabacco Giuseppe Calabrese Claudia Bardoni Jessica Evangelista Lorenzo Spaggiari Stefano Margaritora In the last decade, the emergence of effective systemic therapies (ESTs) in the form of both targeted and immuno-based therapies has revolutionized the treatment of patients with advanced stage III and stage IV melanoma. Even though lungs represent the most frequent site of melanoma metastases, only limited data are available...
Source: Cancers - April 25, 2023 Category: Cancer & Oncology Authors: Elisa Meacci Dania Nachira Maria Teresa Congedo Mohsen Ibrahim Gianluca Pariscenti Francesco Petrella Monica Casiraghi Alessandro De Stefani Laura del del Regno Ketty Peris Elizabeth Katherine Anna Triumbari Giovanni Schinzari Ernesto Rossi Leonardo Petra Tags: Article Source Type: research

Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach
Gene expression profiling is increasingly being utilised as a diagnostic, prognostic and predictive tool for managing cancer patients. Single-sample scoring approach has been developed to alleviate instability...
Source: Journal of Translational Medicine - April 13, 2023 Category: Research Authors: Yizhe Mao, Tuba N. Gide, Nurudeen A. Adegoke, Camelia Quek, Nigel Maher, Alison Potter, Ellis Patrick, Robyn P. M. Saw, John F. Thompson, Andrew J. Spillane, Kerwin F. Shannon, Matteo S. Carlino, Serigne N. Lo, Alexander M. Menzies, In ês Pires da Silva, Tags: Research Source Type: research